Loading organizations...
Loading organizations...
Learn which startups ARCH Venture Partners invests in, what size check sizes they write, and who their partners are (e.g. Robert Nelsen).
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venturefunds totaling over $3 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
Key people at ARCH Venture Partners.
ARCH Venture Partners was founded in 1986 by Steven Lazarus (Co-founder and Managing Director, Emeritus Chicago) and Paul L Berns (Founder).
ARCH Venture Partners was founded in 1986 by Steven Lazarus (Co-founder and Managing Director, Emeritus Chicago) and Paul L Berns (Founder).
ARCH Venture Partners is a venture capital firm primarily focused on investing in early-stage life sciences startups that emerge from academic research. Their mission centers on commercializing breakthrough scientific discoveries by partnering with leading scientists and entrepreneurs to transform healthcare and improve human health outcomes. ARCH’s investment philosophy emphasizes building companies around disruptive platform technologies and data-driven biological innovation, particularly in areas such as disease prevention, detection, and treatment. The firm plays a critical role in the startup ecosystem by bridging the gap between academic research and commercial application, fostering innovation that pushes the boundaries of biotechnology and healthcare[3][4].
Founded in 1986, ARCH Venture Partners was co-founded by Robert Nelsen, who remains a managing director and has been instrumental in the firm’s growth and success. Nelsen’s early work involved engaging with university professors and researchers to identify promising technologies and build companies around them. Over time, ARCH evolved to become a leader in life sciences venture capital, with a focus on co-founding companies that leverage cutting-edge science. The firm’s leadership team includes other managing directors such as Keith Crandell and Kristina Burow, who contribute to ARCH’s collaborative approach to commercializing academic innovations[1][2][3][6].
ARCH Venture Partners rides the wave of convergence between artificial intelligence, data science, and biological research, which is accelerating personalized medicine and novel therapeutic development. The timing is critical as advances in computational biology and biotechnology open new frontiers for disease treatment and healthcare delivery. ARCH’s influence extends beyond funding; by commercializing academic research, they help translate scientific breakthroughs into real-world medical solutions, thereby shaping the future of healthcare innovation and expanding the biotech startup ecosystem[3].
Looking ahead, ARCH is well-positioned to capitalize on the growing integration of AI and biology, continuing to back companies that push the envelope in personalized and equitable healthcare. With a recently closed $3 billion fund (Fund XIII) following a nearly $3 billion Fund XII, ARCH has unprecedented capital to support transformative science. Trends such as longevity research, gene editing, and digital health will likely shape their investment focus. ARCH’s role as a pioneer in translating academic science into commercial success suggests their influence will deepen, driving the next generation of biotech breakthroughs and expanding the human healthspan[3].
Key people at ARCH Venture Partners.
